Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

NASDAQ:LPCN opened at $3.06 on Wednesday. The business has a 50 day moving average of $4.30 and a 200 day moving average of $4.56. The company has a market capitalization of $16.36 million, a price-to-earnings ratio of -4.03 and a beta of 1.23. Lipocine has a 1-year low of $2.96 and a 1-year high of $11.79.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC raised its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.